These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1412 related articles for article (PubMed ID: 18951208)

  • 1. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
    Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
    Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
    Bamias A; Papadimitriou C; Efstathiou E; Rodolakis A; Vlahos G; Voulgaris Z; Bozas G; Fountzilas G; Aravantinos G; Razis E; Gika D; Dimopoulos MA
    BMC Cancer; 2006 Sep; 6():228. PubMed ID: 16999858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
    Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
    Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
    Pete I; Szánthó A; Mayer A; Thurzó L; Pulay T
    Orv Hetil; 2003 May; 144(19):919-24. PubMed ID: 12809068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD; Zhang Q; Zhang Y
    Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos HP; Efstathiou E; Salamalekis E; Farmakis D; Skarlos D; Briasoulis E; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2005 May; 97(2):436-41. PubMed ID: 15863142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
    Bell J; Brady MF; Young RC; Lage J; Walker JL; Look KY; Rose GS; Spirtos NM;
    Gynecol Oncol; 2006 Sep; 102(3):432-9. PubMed ID: 16860852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
    Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
    J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
    Hoskins P; Vergote I; Cervantes A; Tu D; Stuart G; Zola P; Poveda A; Provencher D; Katsaros D; Ojeda B; Ghatage P; Grimshaw R; Casado A; Elit L; Mendiola C; Sugimoto A; D'Hondt V; Oza A; Germa JR; Roy M; Brotto L; Chen D; Eisenhauer EA
    J Natl Cancer Inst; 2010 Oct; 102(20):1547-56. PubMed ID: 20937992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
    Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel-based chemotherapy in carcinoma of the fallopian tube.
    Gemignani ML; Hensley ML; Cohen R; Venkatraman E; Saigo PE; Barakat RR
    Gynecol Oncol; 2001 Jan; 80(1):16-20. PubMed ID: 11136563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer.
    De Placido S; Tramontana S; Ferrari E; De Matteis A; Lauria R; Perrone F; Bianco AR; Gallo C; Ricchi P; De Placido G; Pignata S;
    Anticancer Res; 2000; 20(5C):4023-9. PubMed ID: 11268496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.
    Hou JY; Kelly MG; Yu H; McAlpine JN; Azodi M; Rutherford TJ; Schwartz PE
    Gynecol Oncol; 2007 Apr; 105(1):211-7. PubMed ID: 17239941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer?
    Kim JJ; Park JY; Kim DY; Kim JH; Kim YM; Nam JH; Kim YT
    Acta Obstet Gynecol Scand; 2010 May; 89(5):623-8. PubMed ID: 20423275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Teoh D; Monk BJ; Herzog T; Kapp DS; Bell J
    Gynecol Oncol; 2010 Mar; 116(3):307-11. PubMed ID: 19944452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
    J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 71.